Literature DB >> 17524231

Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes.

Ge Liang1, Zhu Jia-Bi, Xiong Fei, Ni Bin.   

Abstract

The objective of this work was to investigate the preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. To decrease toxic effects and improve antitumour efficacy of the drug, docetaxel has been incorporated in liposomes; the formulation, stability and pharmacokinetics of plain docetaxel liposomes (PDLs), PEGylated docetaxel liposomes (PEGDLs) and N-palmitoyl chitosan anchored docetaxel liposomes (NDLs) were compared. NDL was more stable than PDL and PEGDL in-vitro, especially in the presence of serum at 37 degrees C. The concentration of docetaxel in the plasma of rats after intravenous administration of docetaxel injection, PDL, PEGDL and NDL was studied by RP-HPLC. The pharmacokinetic behaviour of docetaxel injection, PDL, PEGDL and NDL were significantly different. These findings suggest that anchored liposomes could increase the stability of docetaxel in-vivo, as compared with plain liposomes, but the improvement was not more significant than PEGylated liposomes. N-Palmitoyl chitosan as a new polymeric membrane to anchor liposome was useful to stabilize liposomes containing anti-tumour drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17524231     DOI: 10.1211/jpp.59.5.0006

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

1.  Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.

Authors:  Xuelei Yin; Yingying Chi; Chuanyou Guo; Shuaishuai Feng; Jinhu Liu; Kaoxiang Sun; Zimei Wu
Journal:  Pharm Res       Date:  2017-07-19       Impact factor: 4.200

2.  Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.

Authors:  Guangxi Zhai; Jun Wu; Guangya Xiang; Wenxue Mao; Bo Yu; Hong Li; Longzhu Piao; L James Lee; Robert J Lee
Journal:  J Nanosci Nanotechnol       Date:  2009-03

3.  Encapsulation of docetaxel in oily core polyester nanocapsules intended for breast cancer therapy.

Authors:  Ibrahima Youm; Xiao Yan Yang; James B Murowchick; Bi-Botti C Youan
Journal:  Nanoscale Res Lett       Date:  2011-12-14       Impact factor: 4.703

4.  Development of Polysorbate 80/Phospholipid mixed micellar formation for docetaxel and assessment of its in vivo distribution in animal models.

Authors:  Hua Song; Hongquan Geng; Jing Ruan; Kan Wang; Chenchen Bao; Juan Wang; Xia Peng; Xueqing Zhang; Daxiang Cui
Journal:  Nanoscale Res Lett       Date:  2011-04-20       Impact factor: 4.703

5.  Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity.

Authors:  Qing Yuan; Jing Han; Wenshu Cong; Ying Ge; Dandan Ma; Zhaoxia Dai; Yaping Li; Xiaolin Bi
Journal:  Int J Nanomedicine       Date:  2014-10-17

6.  Influence of Polymer Composition on the Controlled Release of Docetaxel: A Comparison of Non-Degradable Polymer Films for Oesophageal Drug-Eluting Stents.

Authors:  Paris Fouladian; Franklin Afinjuomo; Mohammad Arafat; Amanda Bergamin; Yunmei Song; Anton Blencowe; Sanjay Garg
Journal:  Pharmaceutics       Date:  2020-05-11       Impact factor: 6.321

Review 7.  Recent Biomedical Approaches for Chitosan Based Materials as Drug Delivery Nanocarriers.

Authors:  Andreea Teodora Iacob; Florentina Geanina Lupascu; Maria Apotrosoaei; Ioana Mirela Vasincu; Roxana Georgiana Tauser; Dan Lupascu; Simona Eliza Giusca; Irina-Draga Caruntu; Lenuta Profire
Journal:  Pharmaceutics       Date:  2021-04-20       Impact factor: 6.321

8.  Evaluation of Chitosan Derivative Microparticles Encapsulating Superparamagnetic Iron Oxide and Doxorubicin as a pH-Sensitive Delivery Carrier in Hepatic Carcinoma Treatment: An in vitro Comparison Study.

Authors:  Meng-Yi Bai; Sung-Ling Tang; Meng-Han Chuang; Ting-Ying Wang; Po-da Hong
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.